Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria

被引:294
作者
Lambert, PA [1 ]
机构
[1] Aston Univ, Birmingham B4 7ET, W Midlands, England
关键词
D O I
10.1046/j.1365-2672.92.5s1.7.x
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Gram-positive bacteria possess a permeable cell wall that usually does not restrict the penetration of antimicrobials. However, resistance due to restricted penetration can occur, as illustrated by vancomycin-intermediate resistant Staphylococcus aureus strains (VISA) which produce a markedly thickened cell wall. Alterations in these strains include increased amounts of nonamidated glutamine residues in the peptidoglycan and it is suggested that the resistance mechanism involves 'affinity trapping' of vancomycin in the thickened cell wall. VISA strains have reduced doubling times, lower sensitivity to lysostaphin and reduced autolytic activity, which may reflect changes in the D-alanyl ester content of the wall and membrane teichoic acids. Mycobacterial cell walls have a high lipid content, which is assumed to act as a major barrier to the penetration of antimicrobial agents. Relatively hydrophobic antibiotics such as rifampicin and fluoroquinolones may be able to cross the cell wall by diffusion through the hydrophobic bilayer composed of long chain length mycolic acids and glycolipids. Hydrophilic antibiotics and nutrients cannot diffuse across this layer and are thought to use porin channels which have been reported in many species of mycobacteria. The occurrence of porins in a lipid bilayer supports the view that the mycobacterial wall has an outer membrane analogous to that of Gram-negative bacteria. However, mycobacterial porins are much less abundant than in the Gram-negative outer membrane and allow only low rates of uptake for small hydrophilic nutrients and antibiotics.
引用
收藏
页码:46S / 54S
页数:9
相关论文
共 57 条
[1]   INHA, A GENE ENCODING A TARGET FOR ISONIAZID AND ETHIONAMIDE IN MYCOBACTERIUM-TUBERCULOSIS [J].
BANERJEE, A ;
DUBNAU, E ;
QUEMARD, A ;
BALASUBRAMANIAN, V ;
UM, KS ;
WILSON, T ;
COLLINS, D ;
DELISLE, G ;
JACOBS, WR .
SCIENCE, 1994, 263 (5144) :227-230
[2]  
Bidnenko E, 1998, APPL ENVIRON MICROB, V64, P3059
[3]   Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides [J].
Boshoff, HIM ;
Mizrahi, V .
JOURNAL OF BACTERIOLOGY, 2000, 182 (19) :5479-5485
[4]  
Bottger E C, 1994, Trends Microbiol, V2, P416, DOI 10.1016/0966-842X(94)90622-X
[5]   A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates [J].
Boyle-Vavra, S ;
Labischinski, H ;
Ebert, CC ;
Ehlert, K ;
Daum, RS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :280-287
[6]   THE ENVELOPE OF MYCOBACTERIA [J].
BRENNAN, PJ ;
NIKAIDO, H .
ANNUAL REVIEW OF BIOCHEMISTRY, 1995, 64 :29-63
[7]   The antibacterial properties of secreted phospholipases A2 [J].
Buckland, AG ;
Wilton, DC .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1488 (1-2) :71-82
[8]   CAN PENICILLINS AND OTHER BETA-LACTAM ANTIBIOTICS BE USED TO TREAT TUBERCULOSIS [J].
CHAMBERS, HF ;
MOREAU, D ;
YAJKO, D ;
MIICK, C ;
WAGNER, C ;
HACKBARTH, C ;
KOCAGOZ, S ;
ROSENBERG, E ;
HADLEY, WK ;
NIKAIDO, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (12) :2620-2624
[9]   pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis:: Spread of a monoresistant strain in Quebec, Canada [J].
Cheng, SJ ;
Thibert, L ;
Sanchez, T ;
Heifets, L ;
Zhang, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :528-532
[10]   Research and development of antibacterial agents [J].
Chopra, I .
CURRENT OPINION IN MICROBIOLOGY, 1998, 1 (05) :495-501